DDInter1055 DDInter1409
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is downregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) causes {v} (Side Effect) Hot flush
Hot flush {u} (Side Effect) is caused by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemtuzumab ozogamicin
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) causes Hot flush (Side Effect) and Hot flush (Side Effect) is caused by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Gemtuzumab ozogamicin and Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a